Cargando…

Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy

BACKGROUND: Rolapitant, a novel neurokinin‐1 receptor antagonist, provided effective protection against chemotherapy‐induced nausea and vomiting (CINV) in a randomized, double‐blind phase 3 trial of patients receiving moderately emetogenic chemotherapy or an anthracycline and cyclophosphamide regime...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hesketh, Paul J., Schnadig, Ian D., Schwartzberg, Lee S., Modiano, Manuel R., Jordan, Karin, Arora, Sujata, Powers, Dan, Aapro, Matti
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084806/ https://www.ncbi.nlm.nih.gov/pubmed/27176138 http://dx.doi.org/10.1002/cncr.30054

Ejemplares similares

Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations
por: Rapoport, Bernardo Leon, et al.
Publicado: (2017)

Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy
por: Chasen, Martin, et al.
Publicado: (2016)

Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy
por: Navari, Rudolph M., et al.
Publicado: (2018)

Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting
por: Navari, Rudolph M, et al.
Publicado: (2018)

Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting
por: Rapoport, Bernardo Leon
Publicado: (2017)

Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)
por: Rashad, Noha, et al.
Publicado: (2017)

A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting
por: Hesketh, Paul J., et al.
Publicado: (2015)

Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant
por: Barbour, S., et al.
Publicado: (2017)

The role of neurokinin-1 (substance P) antagonists in the prevention of postoperative nausea and vomiting
por: Okafor, Dionne, et al.
Publicado: (2017)

Evaluation of a Neurokinin-1 Antagonist in Preventing Multiple-day Cisplatin-induced Nausea and Vomiting
por: Li, Quanfu, et al.
Publicado: (2018)

Neurokinin-1 receptor antagonists for postoperative nausea and vomiting: a systematic review and meta-analysis
por: Murakami, Chiaki, et al.
Publicado: (2020)

Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK(1)) receptor antagonists
por: Bošnjak, Snežana M., et al.
Publicado: (2017)

Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV)
por: Baron-Hay, Sally, et al.
Publicado: (2019)

Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting
por: Lim, Chae Seong, et al.
Publicado: (2013)

Neurokinin-1 Receptor Antagonists in Preventing Postoperative Nausea and Vomiting: A Systematic Review and Meta-Analysis
por: Liu, Meng, et al.
Publicado: (2015)

Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—introduction
por: Aapro, Matti
Publicado: (2018)

Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—concluding thoughts
por: Aapro, Matti
Publicado: (2018)

Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice
por: Aapro, Matti, et al.
Publicado: (2022)

Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
por: Zelek, Laurent, et al.
Publicado: (2023)

Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis
por: Yamamoto, Senri, et al.
Publicado: (2022)

The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting
por: Dranitsaris, G., et al.
Publicado: (2017)

Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy
por: Shimokawa, Mototsugu, et al.
Publicado: (2022)

Efficacy of Olanzapine 5 mg versus 10 mg for the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving High Emetic Risk Chemotherapy without Neurokinin-1 Receptor Antagonist
por: Sukauichai, Sitthi, et al.
Publicado: (2022)

Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy‐Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy
por: Schwartzberg, Lee, et al.
Publicado: (2019)

Prophylactic Management of Radiation-Induced Nausea and Vomiting
por: Feyer, Petra, et al.
Publicado: (2015)

The incidence of anticipatory nausea and vomiting after repeat cycle chemotherapy: the effect of granisetron.
por: Aapro, M. S., et al.
Publicado: (1994)

Oncologist perspectives on chemotherapy‐induced nausea and vomiting (CINV) management and outcomes: A quantitative market research‐based survey
por: Aapro, Matti, et al.
Publicado: (2018)

A real-world study to evaluate the safety and efficacy of three injectable neurokinin-1 receptor antagonist formulations for the prevention of chemotherapy-induced nausea and vomiting in cancer patients
por: Dranitsaris, George, et al.
Publicado: (2022)

Adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer
por: Watanabe, Yuko, et al.
Publicado: (2021)

Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy
por: Miya, Toshimichi, et al.
Publicado: (2016)

A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin‐Based Chemotherapy‐Induced Nausea and Vomiting in Japan
por: Iihara, Hirotoshi, et al.
Publicado: (2019)

Palonosetron as an anti-emetic and anti-nausea agent in oncology
por: Aapro, Matti S
Publicado: (2007)

Postoperative nausea and vomiting
por: Moon, Young Eun
Publicado: (2014)

Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials
por: Celio, Luigi, et al.
Publicado: (2012)

Morphological and Skeletal Abnormalities Induced by Rolapitant: An Antiemetic Agent
por: Solanki, Sohel, et al.
Publicado: (2022)

Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis
por: Hayashi, Toshinobu, et al.
Publicado: (2021)

Work loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxis
por: Schwartzberg, Lee, et al.
Publicado: (2023)

Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective
por: Nilsson, Jonas, et al.
Publicado: (2022)

Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials
por: Yamamoto, Senri, et al.
Publicado: (2021)

Anticipatory nausea in cyclical vomiting
por: McRonald, Fiona E, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_lqb64kk0aeq18ve0l1ici87jvq